Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab alone and with atezolizumab in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia
2023-506820-10-00Phase 2Completed
- Sponsor
- Genentech
- Start
- Jun 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of mosunetuzumab in mature B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Genentech. Primary endpoints: Incidence and nature of dose-limiting toxicities with mosunetuzumab monotherapy, Incidence and nature of dose-limiting toxicities with mosunetuzumab plus atezolizumab and 6 more. Started Jun 2024; status: completed.
02
Drugs
mosunetuzumab
03
Conditions
mature B-cell lymphomachronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-506820-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506820-10-00.